Featured Publications
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers
Kim H, Nguyen N, Turner K, Wu S, Gujar A, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, Amin S, Yi E, Menghi F, Schulte J, Henssen A, Chang H, Beck C, Mischel P, Bafna V, Verhaak R. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nature Genetics 2020, 52: 891-897. PMID: 32807987, PMCID: PMC7484012, DOI: 10.1038/s41588-020-0678-2.Peer-Reviewed Original ResearchConceptsOncogene amplificationPoor outcomeCancer typesEcDNA amplificationShorter survivalCancer patientsMost cancer typesExtrachromosomal DNA amplificationsClinical impactMultiple cancersPatientsNormal tissuesCancerTranscript fusionsEnhanced chromatin accessibilityIntratumoral genetic heterogeneityOncogene transcriptionChromosomal amplificationOutcomesGenetic heterogeneityHigh levelsDNA amplificationTissue typesBlood
2024
Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location
Küçükosmanoglu A, van der Borden C, de Boer L, Verhaak R, Noske D, Wurdinger T, Radonic T, Westerman B. Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location. Molecular Oncology 2024, 18: 2407-2422. PMID: 38757376, PMCID: PMC11459034, DOI: 10.1002/1878-0261.13636.Peer-Reviewed Original ResearchComposite mutationCo-mutationsMutation-specific drugsCell line dataChromosomal locationSub-clonal populationsGenetic heterogeneitySub-clonesTherapy resistanceSelection pressureGenetic eventsStratify patientsKRAS geneResistance-causing mutationsCancer patientsBiopsy samplesMutationsPatientsGenesPrecision medicineTherapyRiskChromosomeBiopsyBRAF